Parul Tewatia, B.K. Malik and Shakti Sahi Pages 623 - 640 ( 18 )
β3 Adrenergic receptor (β3-AR), is a potential therapeutic target for the treatment of type II diabetes and obesity. We report the identification of novel compounds as β3-AR agonists by integrating different approaches of energetic analysis, structure based pharmacophore designing and virtual screening. In a step wise filtering protocol, structure based virtual screening of 2,33,450 compounds was done. These molecules were docked into the active site of the receptor utilizing three levels of accuracy; ligands passing the HTVS (high throughput virtual screening) step were subsequently analyzed in Glide SP (Standard Precision) and finally in Glide XP (Extra Precision) to estimate the receptor ligand binding affinities. In the second step a total of 300 pharmacophore hypotheses were generated from a set of known and diverse β3-AR agonists. The best hypothesis showed six features: three hydrogen bond acceptors, one positively charged group, and two aromatic rings. To cross validate, pharmacophore filtering was done on the set of shortlisted compounds from structure based VS (virtual screening). The different screening techniques employed were validated using enrichment factor calculations. The energetic based Pharmacophore performed fairly well at distinguishing active from the inactive compounds and yielded a greater diversity of active molecules whereas the number of actives retrieved in the case of structure based screening was the highest.
Beta 3 adrenergic receptor, enrichment factor, pharmacophore, virtual screening, type II diabetes, β3-AR, e-pharmacophore modeling, Glide SP, Glide XP, Virtual Screening
School of Biotechnology, Gautam Buddha University, Greater Noida, UP, India.